Article Details
Retrieved on: 2025-01-23 15:30:31
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Biotechnology company Insilico Medicine has announced the dosing of the first patient in a global Phase I trial of its newest mesothelioma drug ...
Article found on: mesothelioma.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here